170 related articles for article (PubMed ID: 31364872)
1. Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA).
Lenderking WR; Lin H; Speck RM; Zhu Y; Huang H; Huang J; Kerstein D; Langer CJ
Future Oncol; 2019 Aug; 15(24):2841-2855. PubMed ID: 31364872
[No Abstract] [Full Text] [Related]
2. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
[No Abstract] [Full Text] [Related]
3. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
4. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
[TBL] [Abstract][Full Text] [Related]
5. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
Beaumont JL; Lin HM; Goodman E; Yu H; Geiger A; Hudgens S
Value Health; 2024 Feb; 27(2):182-189. PubMed ID: 37951539
[TBL] [Abstract][Full Text] [Related]
6. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
7. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
[TBL] [Abstract][Full Text] [Related]
8. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
9. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR
J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456
[TBL] [Abstract][Full Text] [Related]
10. Brigatinib in
Heredia D; Barrón F; Cardona AF; Campos S; Rodriguez-Cid J; Martinez-Barrera L; Alatorre J; Salinas MÁ; Lara-Mejia L; Flores-Estrada D; Arrieta O
Future Oncol; 2021 Jan; 17(2):169-181. PubMed ID: 32986959
[No Abstract] [Full Text] [Related]
11. Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Exposure-Response Analyses of Pivotal ALTA Study.
Gupta N; Wang X; Offman E; Rich B; Kerstein D; Hanley M; Diderichsen PM; Zhang P; Venkatakrishnan K
CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):718-730. PubMed ID: 33185028
[TBL] [Abstract][Full Text] [Related]
12. Brigatinib-induced tuberculosis reactivation: A case report.
Keş V; Sütcüoğlu O; Gürler F; Yazıcı O; Özet A
Curr Probl Cancer; 2021 Dec; 45(6):100738. PubMed ID: 33867154
[TBL] [Abstract][Full Text] [Related]
13. Brigatinib for
Ali R; Arshad J; Palacio S; Mudad R
Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
[TBL] [Abstract][Full Text] [Related]
14. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
15. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
16. Brigatinib: First Global Approval.
Markham A
Drugs; 2017 Jul; 77(10):1131-1135. PubMed ID: 28597393
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC.
Gupta N; Reckamp KL; Camidge DR; Kleijn HJ; Ouerdani A; Bellanti F; Maringwa J; Hanley MJ; Wang S; Zhang P; Venkatakrishnan K
Clin Transl Sci; 2022 May; 15(5):1143-1154. PubMed ID: 35041775
[TBL] [Abstract][Full Text] [Related]
18. Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients.
Geraud A; Mezquita L; Bigot F; Caramella C; Planchard D; Le Pechoux C; Besse B
J Thorac Oncol; 2018 Nov; 13(11):e215-e217. PubMed ID: 29885478
[No Abstract] [Full Text] [Related]
19. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S; Shaw AT; Besse B; Felip E; Solomon BJ; Soo RA; Bearz A; Gadgeel SM; Lin CC; Kao S; Seto T; Masters ET; Abbattista A; Clancy JS; Thurm H; Reisman A; Peltz G; Ross Camidge D
Lung Cancer; 2020 Jun; 144():10-19. PubMed ID: 32344248
[TBL] [Abstract][Full Text] [Related]
20. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
Sakamoto MR; Honce JM; Lindquist DL; Camidge DR
Clin Lung Cancer; 2019 Mar; 20(2):e133-e136. PubMed ID: 30578110
[No Abstract] [Full Text] [Related]
[Next] [New Search]